AHR and prostate cancer: Although we have demonstrated that prostate cancer cells use the same TDO2-Kyn-AhR signalling pathway to both protect dormant cells from ADT-induced cell death and promote the aggressive growth of recurrent prostate cancer cells in different phases of tumour progression, this pathway clearly activates different sets of genes to modulate tumour dormancy and recurrence.